4
Changes in Ownership
4D Molecular Therapeutics, Inc. Filed Acc 0001193125-26-354313
Chief Legal Officer sold 3,270 shares at an average $12.10 ($39,567)
- Chief Legal Officer acquired 3,270 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bizily Scott Chief Legal Officer | 2026-08-13 | Option exercise 10b5-1 | +1,635 | $4.14 | $6,769 | 10,252 | D: show line 1 in the form |
| Bizily Scott Chief Legal Officer | 2026-08-13 | Sale 10b5-1 | −1,635 | $12.00 | $19,620 | 8,617 | D: show line 2 in the form |
| Bizily Scott Chief Legal Officer | 2026-08-17 | Option exercise 10b5-1 | +1,635 | $4.14 | $6,769 | 10,252 | D: show line 3 in the form |
| Bizily Scott Chief Legal Officer | 2026-08-17 | Sale 10b5-1 | −1,635 | $12.20 | $19,947 | 8,617 | D: show line 4 in the form |
| Open-market sales · 3,270 sh · avg $12.10 · $39,567 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Bizily Scott Chief Legal Officer | 2026-08-13 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,635 | 61,336 | D: show line 5 in the form | |||||
| Bizily Scott Chief Legal Officer | 2026-08-17 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,635 | 59,701 | D: show line 6 in the form |
Loading xslF345X06/ownership.xml…